ClinicalTrials.gg
RecruitingNCT07171034Updated May 26, 2026

A Phase I Study of KLA318-2 Nanocrystal Injection

A Phase 1 interventional study of KLA318-2 Nanocrystal Injection and Celebrex Capsule in Healthy Participants, sponsored by Hunan Kelun Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Hunan Kelun Pharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety,tolerability and pharmacokinetics properties of KLA318-2 Nanocrystal Injection after a single intravenous injection in healthy participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy
03

In context

Lead sponsor

Hunan Kelun Pharmaceutical Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Health participants (Age: 18\~45 years);
  2. Body Weight: Male≥50.0kg, Female≥45.0kg; 18.5 ≤≤ 28.0;
  3. Normal , showing no deviations, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Allergy or Drug ;
  2. Medical History;
  3. Gastrointestinal ulcers or gastrointestinal bleeding;
  4. History of any surgery within 4 weeks;
  5. History of any Medication within 14 days;
  6. History of any drug interactions with celecoxib within 30 days;
  7. History of any clinical study within 3 months;
  8. History of any vaccine within 1 month;
  9. History of any drug abuse, or positive drugs of abuse test result;
  10. Subjects with difficult venous blood collection/intolerance to venipuncture, or with a history of needle phobia/blood phobia;
  11. Massive blood loss (> 200 mL) in the past 3 months;
  12. Special requirements for diet;
  13. Heavy smoker ( more than 3 cigarettes/day) within 3 months;
  14. History of alcohol abuse,or heavy alcohol intake (more than 14 units a week) within 6 months, or positive alcohol test;
  15. Heavy caffeine intake;
  16. History of grapefruit, xanthine-rich foods intake within 7 days;
  17. Female participants are pregnant or lactating;
  18. History of unprotected sex within 2 weeks.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    KLA318-2 Nanocrystal Injection 60mg

    12 participants receive KLA318-2 60mg

    Drug: KLA318-2 Nanocrystal Injection

  • Active comparator
    KLA318-2 Nanocrystal Injection 120mg

    Period 1, 6 participants receive KLA318-2 120mg → 6 participants receive Celebrex Capsule 200mg; Period 2, 6 participants receive Celebrex Capsule 200mg → 6 participants receive KLA318-2 120mg

    Drug: KLA318-2 Nanocrystal Injection · Drug: Celebrex Capsule

  • Active comparator
    KLA318-2 Nanocrystal Injection 180mg

    Period 1, 6 participants receive KLA318-2 180mg → 6 participants receive Celebrex Capsules 400mg; Period 2, 6 participants receive Celebrex Capsules 400mg → 6 participants receive KLA318-2 180mg

    Drug: KLA318-2 Nanocrystal Injection · Drug: Celebrex Capsule

  • Experimental
    KLA318-2 Nanocrystal Injection 240mg

    12 participants receive KLA318-2 240mg

    Drug: KLA318-2 Nanocrystal Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs)

    Time frame: UP to Day 14

Secondary outcomes

  1. PK parameter Cmax

    Maximum peak plasma concentration (Cmax) after single dose and in a steady state after multiple doses

    Time frame: UP to Day 3

  2. PK parameter Tmax

    Time of Cmax (Tmax) after single dose and in a steady state after multiple doses

    Time frame: UP to Day 3

  3. PK parameter AUC0-t

    Area under the concentration-time curve (AUC0-t) from time zero to time "t" after single dose and in a steady state after multiple doses

    Time frame: UP to Day 3

  4. PK parameter AUC0-∞

    AUC from time zero to infinity (AUC0-∞) after single dose and in a steady state after multiple doses

    Time frame: UP to Day 3

  5. PK parameter t1/2

    Terminal-phase elimination half-life (t1/2) after single dose and in a steady state after multiple doses

    Time frame: UP to Day 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for May 2026, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 12, 2025
StartActual
Sep 1, 2025
Primary completionEst.
May 31, 2026
CompletionEst.
May 31, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07171034
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Sep 1, 2025
Primary completion
May 31, 2026 (estimated)
Completion
May 31, 2026 (estimated)
Last update
May 26, 2026

Study contacts

Wei Qi
Contact
qiw@kelun.com
028-82339360

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion